Connect your AI

Arcus Biosciences RCUS Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers SquibbBMY

$1.1B-43.5%

Merck & Co.MRK

$3.92B+56.7%

Regeneron PharmaceuticalsREGN

$1.08B+3.2%

AbbVieABBV

$3.83B+134%

ArriVent BioPharma, Inc.AVBP

-$41.89M+38.4%

ImmunomeIMNM

-$58.64M-10.5%

Other financials

Income statement

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

Market cap$3.8B+317%

Enterprise value$3.72B+376%

P/S16.1×+9.6×

Profitability

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arcus Biosciences's operating cash flow?: Arcus Biosciences (RCUS) reported operating cash flow of -$138M in Q1 2026.
How has Arcus Biosciences's operating cash flow changed year-over-year?: Arcus Biosciences's operating cash flow decreased by 4.5% year-over-year, from -$132M to -$138M.
What is the long-term trend for Arcus Biosciences's operating cash flow?: Over 2 years (2021 to 2025), Arcus Biosciences's operating cash flow has grown at a 37.2% compound annual growth rate (CAGR), from -$256M to -$482M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.